Sfoglia per Autore
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia
2004 BACCARANI M.; MARTINELLI G.; ROSTI G.; TRABACCHI E.; TESTONI N.; BASSI S.; AMABILE M.; SOVERINI S.; CASTAGNETTI F.; CILLONI D.; IZZO B.; DE VIVO A.; MESSA E.; BONIFAZI F.; POERIO A.; LUATTI S.; GIUGLIANO E.; ALBERTI D.; FINCATO G.; RUSSO D.; PANE F.; SAGLIO G.; GIMEMA WORKING PARTY ON CHRONIC MYELOID LEUKEMIA
Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia on Behalf of the GIMEMA CML WP.
2005 Iacobucci, I; Testoni, N; Rosti, G; Amabile, M; Poerio, A; Soverini, S; Colarossi, S; Gnani, A; Ottaviani, E; Castagnetti, F; Terragna, C; Renzulli, M; Grafone, T; Cilloni, D; Pane, F; Saglio, G; Baccarani, M; Martinelli, G
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia
2005 Soverini S; Martinelli G; Rosti G; Bassi S; Amabile M; Poerio A; Giannini B; Trabacchi E; Castagnetti F; Testoni N; Luatti S; de Vivo A; Cilloni D; Izzo B; Fava M; Abruzzese E; Alberti D; Pane F; Saglio G; Baccarani M.
Leucemia mieloide cronica: terapia molecolare
2005 Rosti G.; Castagnetti F.; Bosi C.; Rondoni M.; Giannoulia P.; Baccarani M.
Presence or the Emergence of a F317L BCR-ABL Mutation May Be Associated With Resistance to Dasatinib in Philadelphia Chromosome Positive Leukemia
2006 S. Soverini;G. Martinelli;S. Colarossi;A. Gnani;F. Castagnetti;G. Rosti;C. Bosi;S. Paolini;M. Rondoni;P. P. Piccaluga;F. Palandri;P. Giannoulia;G. Marzocchi;S. Luatti;N. Testoni;I. Iacobucci;D. Cilloni;G. Saglio;M. Baccarani
Dual Src/Abl inhibitor SKI-606 binding mode in BCR-ABL kinase hypothesized on the basis of molecular docking studies
2006 Soverini S.; Tasco G.; Grafone T.; Colarossi S.; Gnani A.; Rosti G.; Castagnetti F.; Palandri F.; Rondoni M.; Poerio A.; Iacobucci I.; Amabile M.; Baccarani M.; Casadio R.; Martinelli G.
Binding Mode Of The Novel Dual SRC and ABL Inhibitor SKI-606 To The BCR-ABL Kinase As Predicted By Molecular Docking Studies
2006 Soverini S.; Tasco G.; Grafone T.; Colarossi S.; Gnani A.; Rosti G.; Castagnetti F.; Palandri F.; Rondoni M.; Poerio A.; Iacobucci I.; Amabile M.; Baccarani M.; Casadio R.; Martinelli G.
Contribution Of ABL Kinase Domain Mutations To Imatinib Resistance In Different Subsets Of Philadelphia-Positive Patients. By The GIMEMA Working Party On Chronic Myeloid Leukemia
2006 Soverini S; Colarossi S; Gnani A; Rosti G; Castagnetti F; Poerio A; Iacobucci I; Amabile M; Abruzzese E; Orlandi E; Radaelli F; Ciccone F; Tiribelli M; di Lorenzo R; Caracciolo C; Izzo B; Pane F; Saglio G; Baccarani M; Martinelli G; on behalf of the GIMEMA Working Party on Chronic Myeloid Leukemia (GIMEMA-CML)
Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients
2006 MARTINELLI G; IACOBUCCI I; ROSTI G; PANE F; AMABILE M; CASTAGNETTI F; CILLONI D; SOVERINI S; TESTONI N; SPECCHIA G; MERANTE S; ZACCARIA A; FRASSONI F; SAGLIO G; BACCARANI M.
Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain
2007 Soverini S; Colarossi S; Gnani A; Castagnetti F; Rosti G; Bosi C; Paolini S; Rondoni M; Piccaluga PP; Palandri F; Giannoulia P; Marzocchi G; Luatti S; Testoni N; Iacobucci I; Cilloni D; Saglio G; Baccarani M; Martinelli G.
Long-term molecular responses to imatinib in patients with chronic myeloid leukemia: comparison between complete cytogenetic responders treated in early and in late chronic phase
2007 Palandri F, Iacobucci I, Quarantelli F, Castagnetti F, Cilloni D, Baccarani M; GIMEMA Working Party on CML.
Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party.
2007 Rosti G; Iacobucci I; Bassi S; Castagnetti F; Amabile M; Cilloni D; Poerio A; Soverini S; Palandri F; Rege Cambrin G; Iuliano F; Alimena G; Latagliata R; Testoni N; Pane F; Saglio G; Baccarani M; Martinelli G.
Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL
2007 Soverini S; Martinelli G; Colarossi S; Gnani A; Rondoni M; Castagnetti F; Paolini S; Rosti G; Baccarani M.
Decision making at diagnosis in chronic myeloid leukemia
2007 Baccarani M.; Palandri F.; Castagnetti F.; Pusiol A.
Bcr-Abl Positive Chronic Myeloid Disorders. Risk stratification Models, Prognostic Variables
2007 Baccarani M.; Castagnetti F.; Iacobucci I.; Palandri F.; Pusiol A.
Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance
2007 Martinelli G.; Iacobucci I.; Soverini S.; Palandri F.; Castagnetti F.; Rosti G.; Baccarani M.
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML.
2008 Palandri F; Iacobucci I; Martinelli G; Amabile M; Poerio A; Testoni N; Soverini S; Castagnetti F; De Vivo A; Breccia M; Specchia G; Abruzzese E; Martino B; Cilloni D; Saglio G; Pane F; Liberati AM; Rosti G; Baccarani M; GIMEMA Working Party on CML.
Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome
2008 Palandri F, Iacobucci I, Castagnetti F, Testoni N, Poerio A, Amabile M, Breccia M, Intermesoli T, Iuliano F, Rege-Cambrin G, Tiribelli M, Miglino M, Pane F, Saglio G, Martinelli G, Rosti G, Baccarani M; GIMEMA Working Party on CML.
Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up
2008 Palandri F, Castagnetti F, Testoni N, Luatti S, Marzocchi G, Bassi S, Breccia M, Alimena G, Pungolino E, Rege-Cambrin G, Varaldo R, Miglino M, Specchia G, Zuffa E, Ferrara F, Bocchia M, Saglio G, Pane F, Alberti D, Martinelli G, Baccarani M, Rosti G; GIMEMA Working Party on Chronic Myeloid Leukemia
Thyrosin kinase inhibitors: nilotinib
2008 Castagnetti F.; Palandri F.; Gugliotta G.; Poerio A.; Amabile M.; Soverini S.; Martinelli G.; Baccarani M.; Rosti G.
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia | BACCARANI M.; MARTINELLI G.; ROSTI G.; TRABACCHI E.; TESTONI N.; BASSI S.; AMABILE M.; SOVERINI S....; CASTAGNETTI F.; CILLONI D.; IZZO B.; DE VIVO A.; MESSA E.; BONIFAZI F.; POERIO A.; LUATTI S.; GIUGLIANO E.; ALBERTI D.; FINCATO G.; RUSSO D.; PANE F.; SAGLIO G.; GIMEMA WORKING PARTY ON CHRONIC MYELOID LEUKEMIA | 2004-01-01 | BLOOD | - | 1.01 Articolo in rivista | - |
| Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia on Behalf of the GIMEMA CML WP. | Iacobucci, I; Testoni, N; Rosti, G; Amabile, M; Poerio, A; Soverini, S; Colarossi, S; Gnani, A; O...ttaviani, E; Castagnetti, F; Terragna, C; Renzulli, M; Grafone, T; Cilloni, D; Pane, F; Saglio, G; Baccarani, M; Martinelli, G | 2005-01-01 | - | - | 4.02 Riassunto (Abstract) | - |
| ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia | Soverini S; Martinelli G; Rosti G; Bassi S; Amabile M; Poerio A; Giannini B; Trabacchi E; Castagn...etti F; Testoni N; Luatti S; de Vivo A; Cilloni D; Izzo B; Fava M; Abruzzese E; Alberti D; Pane F; Saglio G; Baccarani M. | 2005-01-01 | JOURNAL OF CLINICAL ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Leucemia mieloide cronica: terapia molecolare | Rosti G.; Castagnetti F.; Bosi C.; Rondoni M.; Giannoulia P.; Baccarani M. | 2005-01-01 | - | Poletto Editore | 2.01 Capitolo / saggio in libro | - |
| Presence or the Emergence of a F317L BCR-ABL Mutation May Be Associated With Resistance to Dasatinib in Philadelphia Chromosome Positive Leukemia | S. Soverini;G. Martinelli;S. Colarossi;A. Gnani;F. Castagnetti;G. Rosti;C. Bosi;S. Paolini;M. Ron...doni;P. P. Piccaluga;F. Palandri;P. Giannoulia;G. Marzocchi;S. Luatti;N. Testoni;I. Iacobucci;D. Cilloni;G. Saglio;M. Baccarani | 2006-01-01 | JOURNAL OF CLINICAL ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Dual Src/Abl inhibitor SKI-606 binding mode in BCR-ABL kinase hypothesized on the basis of molecular docking studies | Soverini S.; Tasco G.; Grafone T.; Colarossi S.; Gnani A.; Rosti G.; Castagnetti F.; Palandri F.;... Rondoni M.; Poerio A.; Iacobucci I.; Amabile M.; Baccarani M.; Casadio R.; Martinelli G. | 2006-01-01 | HAEMATOLOGICA | - | 4.02 Riassunto (Abstract) | - |
| Binding Mode Of The Novel Dual SRC and ABL Inhibitor SKI-606 To The BCR-ABL Kinase As Predicted By Molecular Docking Studies | Soverini S.; Tasco G.; Grafone T.; Colarossi S.; Gnani A.; Rosti G.; Castagnetti F.; Palandri F.;... Rondoni M.; Poerio A.; Iacobucci I.; Amabile M.; Baccarani M.; Casadio R.; Martinelli G. | 2006-01-01 | HAEMATOLOGICA | - | 4.02 Riassunto (Abstract) | - |
| Contribution Of ABL Kinase Domain Mutations To Imatinib Resistance In Different Subsets Of Philadelphia-Positive Patients. By The GIMEMA Working Party On Chronic Myeloid Leukemia | Soverini S; Colarossi S; Gnani A; Rosti G; Castagnetti F; Poerio A; Iacobucci I; Amabile M; Abruz...zese E; Orlandi E; Radaelli F; Ciccone F; Tiribelli M; di Lorenzo R; Caracciolo C; Izzo B; Pane F; Saglio G; Baccarani M; Martinelli G; on behalf of the GIMEMA Working Party on Chronic Myeloid Leukemia (GIMEMA-CML) | 2006-01-01 | CLINICAL CANCER RESEARCH | - | 1.01 Articolo in rivista | - |
| Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients | MARTINELLI G; IACOBUCCI I; ROSTI G; PANE F; AMABILE M; CASTAGNETTI F; CILLONI D; SOVERINI S; TEST...ONI N; SPECCHIA G; MERANTE S; ZACCARIA A; FRASSONI F; SAGLIO G; BACCARANI M. | 2006-01-01 | ANNALS OF ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain | Soverini S; Colarossi S; Gnani A; Castagnetti F; Rosti G; Bosi C; Paolini S; Rondoni M; Piccaluga... PP; Palandri F; Giannoulia P; Marzocchi G; Luatti S; Testoni N; Iacobucci I; Cilloni D; Saglio G; Baccarani M; Martinelli G. | 2007-01-01 | HAEMATOLOGICA | - | 1.01 Articolo in rivista | - |
| Long-term molecular responses to imatinib in patients with chronic myeloid leukemia: comparison between complete cytogenetic responders treated in early and in late chronic phase | Palandri F, Iacobucci I, Quarantelli F, Castagnetti F, Cilloni D, Baccarani M; GIMEMA Working Par...ty on CML. | 2007-01-01 | HAEMATOLOGICA | - | 1.01 Articolo in rivista | - |
| Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party. | Rosti G; Iacobucci I; Bassi S; Castagnetti F; Amabile M; Cilloni D; Poerio A; Soverini S; Palandr...i F; Rege Cambrin G; Iuliano F; Alimena G; Latagliata R; Testoni N; Pane F; Saglio G; Baccarani M; Martinelli G. | 2007-01-01 | HAEMATOLOGICA | - | 1.01 Articolo in rivista | - |
| Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL | Soverini S; Martinelli G; Colarossi S; Gnani A; Rondoni M; Castagnetti F; Paolini S; Rosti G; Bac...carani M. | 2007-01-01 | THE LANCET ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Decision making at diagnosis in chronic myeloid leukemia | Baccarani M.; Palandri F.; Castagnetti F.; Pusiol A. | 2007-01-01 | HEMATOLOGY EDUCATION | - | 1.01 Articolo in rivista | - |
| Bcr-Abl Positive Chronic Myeloid Disorders. Risk stratification Models, Prognostic Variables | Baccarani M.; Castagnetti F.; Iacobucci I.; Palandri F.; Pusiol A. | 2007-01-01 | - | Informa healthcare - Taylor & Francis publishers | 2.01 Capitolo / saggio in libro | - |
| Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance | Martinelli G.; Iacobucci I.; Soverini S.; Palandri F.; Castagnetti F.; Rosti G.; Baccarani M. | 2007-01-01 | BIOLOGICS | - | 1.01 Articolo in rivista | Martinelli_Biologics2007.pdf |
| Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. | Palandri F; Iacobucci I; Martinelli G; Amabile M; Poerio A; Testoni N; Soverini S; Castagnetti F;... De Vivo A; Breccia M; Specchia G; Abruzzese E; Martino B; Cilloni D; Saglio G; Pane F; Liberati AM; Rosti G; Baccarani M; GIMEMA Working Party on CML. | 2008-01-01 | JOURNAL OF CLINICAL ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome | Palandri F, Iacobucci I, Castagnetti F, Testoni N, Poerio A, Amabile M, Breccia M, Intermesoli T,... Iuliano F, Rege-Cambrin G, Tiribelli M, Miglino M, Pane F, Saglio G, Martinelli G, Rosti G, Baccarani M; GIMEMA Working Party on CML. | 2008-01-01 | HAEMATOLOGICA | - | 1.01 Articolo in rivista | - |
| Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up | Palandri F, Castagnetti F, Testoni N, Luatti S, Marzocchi G, Bassi S, Breccia M, Alimena G, Pungo...lino E, Rege-Cambrin G, Varaldo R, Miglino M, Specchia G, Zuffa E, Ferrara F, Bocchia M, Saglio G, Pane F, Alberti D, Martinelli G, Baccarani M, Rosti G; GIMEMA Working Party on Chronic Myeloid Leukemia | 2008-01-01 | HAEMATOLOGICA | - | 1.01 Articolo in rivista | - |
| Thyrosin kinase inhibitors: nilotinib | Castagnetti F.; Palandri F.; Gugliotta G.; Poerio A.; Amabile M.; Soverini S.; Martinelli G.; Bac...carani M.; Rosti G. | 2008-01-01 | HEMATOLOGY MEETING REPORTS | - | 1.01 Articolo in rivista | - |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile